Tennessee SB2149 establishes a framework for clinical trials of ibogaine, a Schedule I drug, for treating opioid use disorder and other conditions.
Tennessee SB2149 amends state law to facilitate clinical trials of ibogaine, a Schedule I drug, for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The bill outlines the establishment of a cohort to conduct these trials, the selection process by the Department of Mental Health and Substance Abuse Services, and the criteria for proposal submissions.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.